欢迎访问《微生物与感染》官方网站,今天是
特约专稿

抗体治疗的重生

  • 应天雷 ,
  • 闻玉梅
展开
  • 复旦大学基础医学院医学分子病毒学教育部/卫生部重点实验室,上海 200032

收稿日期: 2018-06-22

  网络出版日期: 2018-01-01

基金资助

国家自然科学基金(31570936)

Revival of therapeutic antibodies

  • YING Tianlei ,
  • WEN Yumei
Expand
  • Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China

Received date: 2018-06-22

  Online published: 2018-01-01

摘要

近年来,治疗性单克隆抗体已成为基础和临床医学研究者及企业关注的热点。目前,针对免疫检查点的治疗性抗体用于肿瘤治疗已显示出较好疗效。在微生物耐药性日益增多、全球突发传染病威胁依然存在及持续性微生物感染难以治愈的当下,抗微生物领域中的抗体治疗正在积极研发中。本文综述了抗体治疗在抗微生物感染领域中的进展,并展望了其应用前景。

本文引用格式

应天雷 , 闻玉梅 . 抗体治疗的重生[J]. 微生物与感染, 2018 , 13(4) : 193 -197 . DOI: 10.3969/j.issn.1673-6184.2018.04.001

Abstract

Recently, therapeutic monoclonal antibodies have become the focus of interest for basic medicine researchers, clinicians and industries. Therapeutic antibodies have been used to block the “check points” in immune responses in tumor patients and have shown their effectiveness. Currently, with the emergence of antibiotic-resistant microbial strains, global threats on acute emerging infections, as well as difficult-to-treat persistent infections, therapeutic antibodies for microbes are also under development. This review introduces the progress on therapeutic antibodies in microbial infections, and the perspectives of this field are also presented.

文章导航

/